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Recombinant human interferon beta 1b (rhIFNβ−1b) is clinically used to treat multiple sclerosis. 
A reversed−phase liquid chromatography (RP−LC) method was carried out on a Jupiter C4 column 
(250 mm × 4.6 mm i.d.). The mobile phase A consisted of 0.1% trifluoroacetic acid (TFA) in water, 
and the mobile phase B was acetonitrile with 0.1% TFA run at a flow rate of 1.0 mL/min. A size 
exclusion liquid chromatography (SE−LC) method was carried out on a BioSep−SEC−S 2000 column 
(300 mm × 7.8 mm i.d.). The mobile phase consisted of 1 mM monobasic potassium phosphate, 8 mM 
sodium phosphate dibasic and 200 mM sodium chloride buffer pH 7.4, run isocratically at a flow rate of  
0.8 mL/min. Retention times were 31.87 and 17.78 min, and calibration curves were linear over the 
concentration range of 1−200 µg/mL (r2 = 0.9998) and 0.50−200 µg/mL (r2 = 0.9999), respectively, for 
RP−LC and SE−LC, with detection at 214 nm. Liquid chromatography (LC) methods were validated 
and employed in conjunction with the in vitro bioassay to assess the content/potency of rhIFNβ−1b, 
contributing to improve the quality control and to ensure the efficacy of the biotherapeutic.
Keywords: Recombinant human Interferon beta 1b. Biotechnology-derived medicine. Bioassay. 
Reversed-phase liquid chromatography. Size-exclusion liquid chromatography.
INTRODUCTION
Interferons (IFNs) are natural proteins produced by 
immune system cells that have antiviral, antiproliferative 
and immunomodulatory propert ies .  Interferon 
betas represent the first class of disease modifying 
therapies (DMTs) for multiple sclerosis (MS) and have 
contributed considerably to the understanding of the 
immunomodulatory mechanisms. Human interferon beta 
(hIFN-β) is a hydrophobic glycoprotein that contains 166 
amino acids produced by fibroblasts. Advances in the 
recombinant DNA technology facilitate the expression 
of hIFN−β resulting in a large-scale production of 
biopharmaceutical formulations. Recombinant human 
interferon beta 1b (rhIFNβ-1b) is engineered as a non-
glycosylated protein in Escherichia coli (E. coli) with 
a serine residue instead of a cysteine at amino acid 
position 17 and lacks the methionine at the N-terminus. 
The substitution at position 17 was made to eliminate 
the free sulfhydryl of cysteine to obtain a product that is 
more stable upon storage. The polypeptide structure is 
composed of 165 amino acids with a molecular mass of 
18.5 kDa. It is currently being used worldwide to treat MS 
in a large number of patients (Mark et al., 1984; Dendrou, 
Fugger, Friese, 2015; EMEA, 2017).
The biological potency of rhIFNβ−1b has been 
assessed by in vitro bioassays using a variety of cells/virus 
systems and has also been used in a collaborative study 
that established the 3rd international standard. An in vitro 
cytopathic bioassay based on the effect of the VSV virus 
cell line (ATCC® No. VR-158™) against the sensitive 
WISH cell line (ATCC® No. CCL-25™) has been widely 
used, evaluating the responses as viable protected cells 
stained with vital dyes such as AlamarBlue or tetrazolium 
salts. The antiproliferative assays using the Daudi cell 
line (ATCC® No. CCL-213™) or A−549 cell line (ATCC® 
No. CCL-185™) were applied to evaluate the potency of 
the biomolecule, measuring the responses with MTT. A 
genetically modified cell line with promoter activation 
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and expression of enzyme markers such as alkaline 
phosphatase was also developed (Borden, Hogan, Voelkel, 
1982; Meager, Das, 2005; Basu et al., 2006). 
Currently, analytical methodologies based on 
biological and physicochemical properties have proven 
to be particularly useful for the analysis of therapeutic 
proteins and have also been applied to correlation studies 
(Qian et al., 2008; Skrlin et al., 2010; Cardoso et al., 2017). 
Reversed-phase liquid chromatography (RP-LC) and size-
exclusion liquid chromatography (SE-LC) methods offer 
a high level of accuracy and sensitivity for the analysis 
of closely related protein variants, degradation products, 
and high-molecular-weight (HMW) substances with 
reduced or absent activity and altered immunogenicity 
(Fekete et al., 2014; Moussa et al., 2016). A gradient RP-
LC method was used to evaluate the long-term stability of 
hIFN-β with 214TP C4 column with detection at 214 nm 
(Geigert et al., 1988). A RP-LC method was performed on 
a Jupiter C4 column, together with a SE−LC method on an 
SEC UPLC column, with UV and fluorescence detection, 
to evaluate the effect of the excipients on the stability 
of the formulation and to characterize and quantitate 
aggregates in preparations of rhIFNβ-1b, thus correlating 
the biophysical characteristics with immunogenicity 
(Abdolvahab et al., 2016a; Abdolvahab et al., 2016b). An 
RP-LC method using a C4 column and an SE-LC using an 
SEC UPLC column were applied to monitor the mechanism 
of aggregation of IFNβ-1b by heating, oxidizing, or seeding 
of an unformulated monomeric solution (Fazeli et al., 
2014). SE-LC using a TSK G2000S column was applied 
to characterize and quantitate aggregates, evaluating 
potential links to any immune response (Barnard, Babcock, 
Carpenter, 2013). A literature search shows the necessity 
of validated methods for the analysis of rhIFNβ-1b to meet 
the acceptance criteria suggested for biotechnology-derived 
proteins (FDA, 2015; EP, 2017).
This research aimed to develop and validate specific, 
stability-indicating RP-LC and SE-LC methods to assess 
the content/potency of rhIFNβ-1b in biopharmaceutical 
formulations; to correlate the results with the in vitro 
bioassay and to evaluate the bioactivity and the cytotoxicity 
of related proteins and HMW substances. This work thus 
will contribute to the development of methods to improve 
the quality control of biotechnology-derived medicine.
MATERIAL AND METHODS
Reagents and chemicals
The standard Interferon Beta Ser17 Mutein, human 
rDNA derived (BRS-IFNβ-1b), WHO 00/574, for 
bioassay, was obtained from the National Institute 
for Biological Standards and Control (NIBSC, Hertz, 
UK) with 64,000 IU per vial. The recombinant human 
biological reference substance of Interferon beta 1b 
(Rec−IFNβ−1b), for physicochemical assays, was supplied 
by United States Biological (Swampscott, Massachusetts, 
USA) with 2 µg/mL. A total of six batches of Betaferon® 
Bayer HealthCare (São Paulo, Brazil), containing 
300 µg/vial  (9.600.000 IU/vial = 9.6 MIU/vial) of 
rhIFNβ-1b, were labeled from 1 to 6. The samples were 
acquired from commercial sources within their shelf−life 
period. Monobasic potassium phosphate, sodium phosphate 
dibasic, sodium chloride, acetonitrile, trifluoroacetic acid 
(TFA), human serum albumin (HSA) and mannitol were 
supplied by Merck (Darmstadt, Germany). Dulbecco’s 
Modified Eagle’s Medium (DMEM), fetal bovine serum 
(FBS) and AlamarBlueTM cell viability reagent were 
acquired from Sigma-Aldrich (St. Louis, MO, USA). All 
chemicals used were of HPLC grade or special analytical 
grade. For all analyses, ultrapure water was purified using 
an Elix 3 coupled to a Milli−Q Gradient A10 system from 
Millipore (Bedford, MA, USA).
Apparatus
RP-LC and SE-LC analyses were performed on 
a Shimadzu LC system (Kyoto, Japan) equipped with 
a CBM−20A system controller, a LC-20 AD pump, a 
DGU-20AS degasser, a SIL-20ACHT autosampler, a CTO 
column oven and a SPD-M20A photodiode array (PDA) 
detector. Peak areas were automatically integrated by the 
computer by using LC Solution version 1.22 SP1 software. 
The absorbance of the in vitro cell culture bioassay 
was measured on a Thermo Scientific Varioskan® Flash 
microplate reader (Vantaa, Finland).
Samples and standard solutions 
A commercial batch of Betaferon® labeled as 300 
µg/vial, equal to 9.6 MIU/vial, was calibrated against 
the BRS-IFNβ-1b and Rec-IFNβ-1b and used as an 
in−house biological reference substance of rhIFNβ-1b 
(BS-IFNβ-1b) for the LC methods. Stock solutions were 
prepared by diluting the BS-IFNβ-1b and samples of 
biopharmaceutical formulations in ultrapure water to 
a final concentration of 50 µg/mL (1.6 MIU/mL) and 
25 µg/mL (0.8 MIU/mL), respectively, for RP-LC and 
SE-LC; and to a range of concentrations starting with 
1 IU/mL of BRS-IFNβ-1b and of BS-IFNβ-1b in culture 
medium DMEM containing 2% (v/v), fetal bovine serum, 
for the cell culture bioassay.
Evaluation of recombinant human interferon beta 1b by liquid chromatography methods and bioassay
Braz. J. Pharm. Sci. 2019;55:e18328 Page 3 / 9
Procedures
Reversed-phase liquid chromatography (RP-LC)
The experiments were performed on a reversed-
phase Phenomenex (Torrance, USA) Jupiter C4 column 
(250 mm × 4.6 mm i.d., with a particle size of 5 µm and 
pore size of 300 Å) maintained at 30 °C. A security guard 
holder was used to protect the analytical column. The 
mobile phase A consisted of 0.1% TFA in water and the 
mobile phase B was 0.1% TFA in acetonitrile and was 
run as follows: time 0 to 0.01 min 38% of B; from 0.01 to 
35 min linear up to 60% of B; from 35.1 to 38 min linear 
down to 38% of B maintained up to 42 min. The flow 
rate was 1 mL/min, with PDA detection at 214 nm. The 
injection volume was 50 µL.
Size-exclusion liquid chromatography (SE-LC)
The experiments were accomplished using a size-
exclusion Phenomenex (Torrance, USA) BioSep-SEC-S 
2000 column (300 mm × 7.8 mm i.d., with a particle size 
of 5 µm and pore size of 145 Å) maintained at 25 °C. A 
security guard holder was used to protect the analytical 
column. The mobile phase consisted of 1 mM monobasic 
potassium phosphate, 8 mM sodium phosphate dibasic; 
200 mM sodium chloride buffer, pH 7.4. The flow rate was 
0.8 mL/min with PDA detection at 214 nm. The injection 
volume was 30 µL.
Antiproliferative assay
The bioassay was performed as described elsewhere 
(Borden, Hogan, Voelkel, 1982) with some adjustments. 
The A-549 cell line of human alveolar adenocarcinoma 
(ATCC® No. CCL-185™) was maintained in DMEM 
culture medium supplemented with 10% (v/v) FBS 
in 75-cm2 flasks. The cells were seeded in 96-well 
Costar® microplates (Corning, NY, USA) at a density of 
1 × 104 cells/mL and dosed upon seeding with four 
concentrations (nine−fold dilution series) starting 
with 1 IU/mL of rhIFNβ-1b. BRS-IFNβ-1b was used 
as standard and to calibrate the BS-IFNβ-1b, and the 
control was DMEM. Briefly, the plates were incubated at 
37 °C, 5% CO2 for 120 h. Then, 20 µL of AlamarBlue
TM 
was added per well, and the plates were incubated for a 
further 4 h. The response was calculated as the difference 
between the absorbances measured at 570 and 600 nm. 
The biological activity was calculated with the parallel 
line statistical method by using CombiStatsTM software 
(EDQM, Council of Europe, Strasbourg, France).
In vitro cytotoxicity test
The assay was performed as described elsewhere 
(Maldaner et al., 2017) based on the neutral red uptake 
(NRU) assay, with the NCTC clone 929 cell line 
(mammalian fibroblasts, ATCC® No. CCL-1™) exposed 
to altered samples of rhIFNβ-1b. The absorbance was 
measured at 540 nm.
Validation of LC methods
Validation of the RP−LC and SE-LC methods was 
performed by using samples of rhIFNβ-1b with a label 
claim of 300 µg/vial (9.6 MIU/vial), and the parameters 
were assessed according to the guidelines (FDA, 2015; 
ICH, 2005). 
Specificity
The specificity of the RP-LC method was assessed 
by subjecting a BS−IFNβ−1b solution and a sample 
of the biopharmaceutical formulation (300 µg/mL) to 
photodegradation by exposing the sample to 200 Wh/m2 
near-UV light in a photostability chamber for 24 h. The 
oxidative condition induced by hydrogen peroxide 3% 
for 3 h was also tested. The solutions were diluted with 
ultrapure water to a final concentration of 50 µg/mL. 
For the SE-LC, a BS-IFNβ-1b solution and a sample 
of biopharmaceutical formulation (300 µg/mL) were 
subjected to neutral hydrolysis (60 °C for 2 h) and shaken 
for 30 min. Solutions were diluted with ultrapure water to 
a final concentration of 25 µg/mL. In addition, possible 
interference from excipients of the biopharmaceutical 
formulation was determined by analyzing a sample that 
contained only placebo (in−house mixture of formulation 
excipients). The specificity of the LC methods was also 
established by determining the peak purity of rhIFNβ-1b 
and degraded forms by overlaying the spectra captured at 
the apex, upslope, and downslope using a PDA detector.
Linearity
The linearity of the methods was determined by 
constructing three independent analytical curves, each with 
eight concentrations of the BS-IFNβ-1b solution. Three 
replicates of 50 µL and 30 µL injections of the reference 
solutions were prepared to verify the repeatability of the 
detector response. The peak areas were plotted against 
the respective concentrations of BS-IFNβ-1b solution to 
obtain the analytical curve. The results were subjected 
to regression analysis by the least squares method to 
calculate the calibration equation and the determination 
coefficient (r²).
Precision and accuracy
Precision was determined by means of repeatability 
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(intra-day) and intermediate precision (inter−days and 
between−analysts). Repeatability was examined by six 
analyses of a sample of rhIFNβ-1b, at concentrations of 
50 and 25 µg/mL for the RP-LC and SE-LC methods, 
respectively, on the same day and under the same 
experimental conditions. The inter-days precision 
was assessed by analysis of two samples of the 
biopharmaceutical formulations on three different 
days. The between-analysts precision was assessed by 
submitting the samples to analysis by different analysts in 
the same laboratory. The accuracy was assessed by analysis 
of the in−house mixture of excipients with known amounts 
of the biomolecules to obtain solutions at concentrations 
of 40, 50 and 60 µg/mL for the RP-LC, and 20, 25 and 
30 µg/mL for the SE-LC methods, equivalent to 80, 100 
and 120%, respectively, of the working concentration 
solutions. The accuracy was calculated as the percentage 
of drug recovered from the formulation and expressed as 
the percentage relative error (bias %).
Detection and quantitation limits
The detection limit (DL) and the quantitation limit 
(QL) were calculated as defined by (ICH, 2005), using the 
mean values of the three independent analytical curves 
determined by a linear-regression model, where the 
factors 3.3 and 10 for the DL and QL, respectively, were 
multiplied by the ratio from the standard deviation of the 
intercept and the slope. The QL was also evaluated in an 
experimental assay.
Robustness
The robustness of an analytical procedure provides 
an indication of its reliability for routine analysis. The 
RP−LC and SE-LC methods were tested analyzing the 
same samples, containing 50 µg/mL and 25 µg/mL, 
respectively, under one-variable-at-a-time (OVAT) 
conditions, to evaluate the described parameters (Tables I 
and III). The stability of sample solutions was tested after 
storage, and any changes in the chromatographic pattern 
were compared with the freshly prepared samples.
System suitability test
The system suitability test was performed to analyze 
five replicate injections of 50 µg/mL and 25 µg/mL BS-
rhIFNβ-1b. The peak area, retention time, theoretical 
plates, and tailing factor (peak symmetry) were measured. 
Analysis of rhIFNβ-1b in biopharmaceutical 
formulations
Biopharmaceutical samples available for clinical 
use, with potency expressed in µg/mL and MIU/mL, 
were identified compared to Rec-IFNβ-1b. For the 
RP-LC and SE-LC methods, the solutions were diluted 
to appropriate concentrations of 50 and 25 µg/mL in 
ultrapure water, respectively, and injected in triplicate, 
and the percentage recoveries were calculated against 
the BS-IFNβ-1b.
RESULTS AND DISCUSSION
Biotherapeutics manufactured by the recombinant 
DNA technology are complex and heterogeneous 
and possess characteristics that are highly dependent 
on the processes used for their manufacture. This 
includes the expression system, raw materials, protein 
production, isolation and purification processes, as well 
as the formulation and storage of the final product. As a 
consequence, even if the proteins are produced using the 
same gene sequence, it is highly likely that the quality of 
the products differs considerably, with potential impact 
on clinical efficacy and safety. Then, an important issue 
for biotechnology−derived medicines is the research 
of biological and LC methods necessary to assure the 
content/potency of the biotherapeutics, selected due to 
their capabilities and validated following the international 
guidelines for the qualitative and quantitative analysis.
Development and optimization of 
chromatographic conditions
Tests were performed to determine which mobile 
phase would lead to satisfactory selectivity and sensitivity 
in a short separation time. For the RP−LC, TFA in water 
and TFA in acetonitrile resulted in higher sensitivity 
related to phosphate buffer, and lower retention time 
compared to sodium phosphate buffer. Resolution was 
improved, using mobile phases containing 0.1% TFA 
in water and 0.1% TFA in acetonitrile. For the SE-LC 
method, a mobile phase composed by 1 mM monobasic 
potassium phosphate, 8 mM sodium phosphate dibasic 
buffer and 200 mM sodium chloride resulted in higher 
sensitivity than phosphate buffer and phosphate buffered 
saline. The optimal wavelength was selected using a 
PDA detector. Typical chromatograms demonstrating 
the resolution of the symmetrical peaks corresponding to 
rhIFNβ-1b are shown in Figure 1 (a, b) and Figure 2 (a, b).
Validation of LC methods 
The  s t ab i l i t y - ind i ca t ing  capac i ty  o f  t he 
RP-LC method was evaluated under oxidative and 
photodegradation conditions, which showed decreases 
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in the area of the main peak (at 31.87 min) and additional 
peaks attributed to deamidated/sulfoxides, with retention 
times at 27.74 and 28.62 min (Figure 1c) and at 27.44 and 
30.07 min (Figure 1d), respectively. The specificity of the 
SE−LC method, evaluated by neutral hydrolysis, showed 
the peak related to the monomer detected at 17.78 min and 
two additional peaks of HMW substances, with retention 
times at 16.58 and 17.69 min (Figure 2c). Moreover, the 
injection of a sample containing only the placebo showed 
one peak at 9.78 min, related to the HSA. Together with 
the peak purity index of 0.9999-1, the data showed that 
the peaks were free of any co−eluting peak and that the 
excipients, mainly HSA, did not interfere in the analysis, 
which confirmed that the LC methods were specific for 
the analysis of rhIFNβ-1b. 
For the RP−LC method,  analyt ical  curves 
were found to be linear over a concentration range of 
1 - 2 0 0  µ g / m L  ( 0 . 0 3 2  -  6 . 4  M I U / m L ) .  T h e 
determination coefficient was calculated as r2 = 0.9998, 
y = (31936 ± 919.76) x − (11051 ± 8647.04), where x is 
concentration and y is the peak absolute area. For the 
SE−LC method, the analytical curves were found to be 
linear over a concentration range of 0.50-200 µg/mL 
(0.016 – 6.4 MIU/mL). The determination coefficient was 
calculated as r2 = 0.9999, y = (231645 ± 165037.74) x – 
(2182 ± 1001.77). 
The precision of the LC methods was studied by 
calculating the mean values and relative standard deviation 
(RSD %). For repeatability, the obtained RSD values were 
0.10 and 0.04%. The inter-days precision was tested, 
giving RSD values of 0.40 and 0.71% for the RP-LC, and 
0.83 and 0.94% for the SE-LC. The between-analysts 
precision was also determined; the RSD values were found 
to be 0.57 and 1.19% for the RP-LC and 0.25 and 0.35% 
for the SE-LC method.
The accuracy was assessed, and the absolute means 
were 100.42 and 100.45% with bias lower than 0.69 and 
0.82% (Table I), respectively, for the RP-LC and SE-LC 
FIGURE 2 – Representative SE−LC chromatograms showing peak 1 = rhIFNβ−1b; peak 2 = human serum albumin; peaks 3 
and 4 = high−molecular−weight substances. (a) Biological reference substance of rhIFNβ−1b. (b) Sample of biopharmaceutical 
formulation, untreated and after: (c) neutral hydrolysis; (d) placebo.
FIGURE 1 – Representative RP−LC chromatograms showing peak 1 = rhIFNβ−1b; peak 2 = human serum albumin; peaks 3 and 
4 = related proteins; peak 5 = hydrogen peroxide. (a) Biological reference substance of rhIFNβ−1b. (b) Sample of biopharmaceutical 
formulation, untreated and after: (c) degradation by hydrogen peroxide; (d) photodegradation; (e) placebo.
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methods; these values showed the accuracy under the 
experimental conditions. 
The DL and QL of the LC methods were calculated 
as 0.47 and 1.57 µg/mL, for the RP−LC and 0.10 and 0. 
34 µg/mL, for the SE-LC. The evaluated experimental 
QL with a precision with error below 5% and accuracy 
within ± 5% (Shabir et al., 2007), was found to be 1 µg/mL 
(0.032 MIU/mL) and 0.50 µg/mL (0.016 MIU/mL), 
respectively, which are suitable for quality control 
analysis.
The results and experimental range of the selected 
variables evaluated for robustness using an OVAT 
approach are given in Tables II and III, together with the 
optimized values, demonstrating that they were within the 
acceptable deviation (RSD ≤ 2%), with non-significant 
differences (p > 0.05), as calculated by analysis of 
variance. The stability tests also showed non-significant 
changes (p > 0.05).
The suitability of the system was tested and the RSD 
values calculated for the retention time, peak symmetry 
and peak area were 0.01, 0.40 and 1.96%, respectively, 
for the RP-LC, and 0.04, 0.28 and 0.22%, respectively, 
for the SE-LC method. The number of theoretical plates 
was 107554, with an RSD of 0.81%, and 9579 with an 
RSD of 0.88%. These results were considered acceptable 
(RSD < 2%). 
Application of the LC methods and bioassay
The validated LC methods were applied to determine 
rhIFNβ-1b in biopharmaceutical formulations, giving 
the content/potencies shown in Table IV, with mean 
TABLE II - Chromatographic conditions and range investigated during robustness test for the RP-LC method
Variable Range investigated rhIFNβ−1b
a  
(%)
RSDb 
(%) Optimized value
TFA (%)
0.05 
0.10 
0.15
98.97 
100.16 
99.13
1.08 
0.94 
1.24
0.10
Temperature ( ºC)
28 
30 
32
99.35 
100.16 
99.35
0.23 
0.04 
0.36
30
Flow rate (mL/min)
0.9 
1.0 
1.1
99.79 
99.39 
99.31
0.19 
0.14 
0.28
1.0
Solution stability
Autosampler 24 h 
2 – 8 ºC 24 h 
2 – 8 ºC 48 h
100.47 
100.05 
100.68
0.56 
0.16 
0.83
– 
– 
–
Wavelength (nm) 190 – 320 – – 214
Mean of three replicates. bRSD = Relative standard deviation.
TABLE I - Accuracy of RP−LC and SE−LC for rhIFNβ−1b in biopharmaceutical formulations
Method
Nominal 
concentration
(µg/mL)
Mean concentration 
measureda
(µg/mL)
RSDb
(%)
Accuracy
(%)
Biasc
(%)
RP−LC 40 40.00 0.03 99.99 −0.01
50 50.30 0.85 100.59 0.59
60 60.41 0.50 100.69 0.69
SE−LC 20 20.16 0.08 100.80 0.82
25 25.04 0.06 100.16 0.16
30 30.12 0.19 100.40 0.40
aMean of three replicates. bRSD = Relative standard deviation. cBias = [(Measured concentration - Nominal concentration)/Nominal 
concentration] × 100.
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values 1.27 and 1.05% higher for RP-LC and SE-LC, 
respectively, compared to the in vitro bioassay. The 
Pearson’s correlation coefficient was calculated, showing 
significant correlation for the RP-LC (r = 0.9626), and the 
SE−LC (r = 0.9367), related to the bioassay. Furthermore, 
biopharmaceutical samples were artificially degraded, as 
described in the section on specificity, were analyzed by 
the LC methods, and subjected to the in vitro bioassay. 
These samples showed bioactivities reduced by 6.50% ± 
3.40 (n = 3) and 44.30% ± 2.15 (n = 3) for the deamidated/
sulfoxides and HMW substances, respectively, except 
for the oxidative condition, which was not tested due to 
the possible interference of H2O2. The results showed the 
capability of each method, which can be apply also to 
biosimilarity studies of rhIFNβ−1b and the recently used 
innovative formulation of beta1a PEGylated interferon 
(Kálmán-Szekeres, Olajos, Ganzler, 2012; Madsen, 
2017). The noninnovator “copy” versions are likely to 
vary in their quality, eg., physicochemical characteristics 
and biological activity, with important implications for 
clinical efficacy and safety (Meager et al., 2011). Then 
the studies showed the potential of each method, and that 
using them in combination represents advancement in 
terms of analytical techniques, contributing also to the 
characterization of this therapeutic biosimilar. 
Cytotoxicity evaluation
The cytotoxicity test was performed on degraded 
forms giving mean IC50 = 8.68 ± 0.71 MIU/mL, 
IC50 = 12.17 ± 0.20 MIU/mL, for photolytic and 
neutral hydrolysis conditions, respectively. Differences 
calculated by Student’s t-test were significant (p < 0.05) 
compared to the intact molecule, which had an IC50 of 
6.89 ± 0.13 MIU/mL. Such evaluations are now necessary, 
mainly due to recent concerns about possible undesirable 
effects in humans resulting from the instability of samples 
during storage (Pineda et al., 2015). 
CONCLUSIONS 
The results of the validation studies show that the LC 
methods are specific, sensitive and accurate, and can be 
initially applied in combination with the in vitro bioassay 
for content/potency assessment of biopharmaceutical 
formulations. Due to the agreement between the results, 
LC methods can be used as alternative for evaluating 
biotechnology processes and through subsequent 
purification steps, to monitor the stability, and to ensure 
the batch-to-batch consistency of the bulk and finished 
biotechnology-derived medicines.
TABLE III - Chromatographic conditions and range investigated during robustness test for the SE-LC method
Variable Range investigated rhIFNβ−1b
a 
(%)
RSDb 
(%) Optimized value
Mobile phase pH
7.0 
7.4 
7.8
99.27 
99.30 
100.55
1.33 
0.60 
1.21
7.4
Monobasic potassium 
phosphate (mM)
0.9 
1.0 
1.1
99.25 
99.59 
100.03
1.20 
0.78 
0.85
1.0
Sodium phosphate dibasic 
(mM)
7.5 
8.0 
8.5
99.56 
100.33 
98.24
0.89 
0.78 
0.84
8.0
Sodium chloride (mM)
180 
200 
220
99.86 
100.10 
100.22
0.94 
0.54 
1.09
200
Flow rate (mL/min)
0.7 
0.8 
0.9
99.95 
99.99 
99.94
0.90 
0.78 
0.89
0.8
Solution stability
Autosampler 24 h 
2 – 8 ºC 24 h 
2 – 8 ºC 48 h
99.46 
99.35 
99.45
1.06 
0.59 
0.91
– 
– 
–
Wavelength (nm) 190 – 320 – – 214
aMean of three replicates. bRSD = Relative standard deviation.
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TABLE IV - Comparative content/potency evaluation of rhIFNβ−1b in biopharmaceutical formulations by bioassay and LC methods
Sample Theoretical Amount
Bioassaya RP−LCa SE−LCa
Potency Confidence intervals Main peak Deamidated/sulfoxides Monomer HMW
(µg) (%) (P = 0.95) (%) (%) (%) (%)
1 300 99.70 (94.20 – 105.60) 100.83 0.81 100.58 0.68
2 300 100.20 (94.20 – 106.70) 100.41 0.59 100.12 0.49
3 300 98.80 (92.90 – 105.00) 100.31 0.46 100.98 0.39
4 300 102.40 (96.90 – 108.10) 104.05 0.36 103.90 0.47
5 300 98.70 (93.30 – 104.50) 99.87 0.78 99.16 0.89
6 300 95.60 (90.20 – 101.30) 97.57 0.99 96.96 0.84
Mean – 99.23 – 100.50 0.73 100.28 0.68
SDb – 2.22 – 2.08 – 2.27 –
2c – 93.70 (85.60 – 102.50) 89.34 7.36 – –
2d – 55.90 (50.80 – 61.60) – – 65.40 11.36
2e – Ntf – 72.08 25.47 – –
aMean of three replicates. bSD = Standard deviation. cUVdegraded. dNeutral hydrolysis. eOxidative condition. fNt = Not tested.
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